Sponsors / KARD
KARD

Kardigan, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
4Trials in this database
11Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)NCT06864104KARDPhase 2Completed2026-01-12Actual
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled StudyNCT07001800KARDPhase 2, Phase 3Recruiting2028-08-31Estimated
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated CardiomyopathyNCT07210723KARDPhase 2, Phase 3Recruiting2027-09Estimated
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe HypertensionNCT07511361KARDPhase 2Recruiting2026-12Estimated

Latest recorded trial changes

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

NCT07511361 · Kardigan, Inc.

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: To assess the effect of tonlamarsen on plasma angiotensinogen (AGT) levels Measure: To assess the systolic blood pressure-lowering effect of tonlamarsen

+ After

Measure: Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions Measure: Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levels

Planned enrollment increased by 40 participants

− Before

100 participants (planned)

+ After

140 participants (planned)

Primary completion date changed

− Before

29 Dec 2026

+ After

Dec 2026

Check registry source
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

NCT07001800 · Kardigan, Inc.

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: (Part A) Change in Aortic Valve Calcium (AVC) from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in AVA as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 from baseline to Week 48

+ After

Measure: (Part A) Change in Aortic Valve Calcium (AVC) score as assessed by non-contrast CT from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in Aortic Valve Area (AVA) as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 by CPET from baseline to Week 48

Planned enrollment decreased by 134 participants

− Before

1410 participants (planned)

+ After

1276 participants (planned)

Phase changed

− Before

PHASE3

+ After

PHASE2, PHASE3

Check registry source